The latest price target for ImmunityBio (NASDAQ:IBRX) was reported by D. Boral Capital on January 16, 2025. The analyst firm set a price target for $30.00 expecting IBRX to rise to within 12 months (a possible 941.67% upside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for ImmunityBio (NASDAQ:IBRX) was provided by D. Boral Capital, and ImmunityBio maintained their buy rating.

There is no last upgrade for ImmunityBio

The last downgrade for ImmunityBio Inc happened on May 12, 2023 when Piper Sandler changed their price target from $10 to $4 for ImmunityBio Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ImmunityBio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ImmunityBio was filed on January 16, 2025 so you should expect the next rating to be made available sometime around January 16, 2026.

While ratings are subjective and will change, the latest ImmunityBio (IBRX) rating was a maintained with a price target of $30.00 to $30.00. The current price ImmunityBio (IBRX) is trading at is $2.88, which is out of the analyst’s predicted range.